Author(s):
Rama chandrapuram Kiranjyothi, Mahalingam Balakrishnan, Kothapalli Bannoth Chandrasekhar
Email(s):
jyothikiran460@gmail.com
DOI:
10.52711/0974-360X.2021.00458 
Address:
Rama chandrapuram Kiranjyothi1*, Mahalingam Balakrishnan2, Kothapalli Bannoth Chandrasekhar3
1Department of Pharmaceutical Analysis and Quality Assurance, Research Scholar,
Jawaharlal Nehru Technological University, Ananthapuramu, Andhra Pradesh., India.
2Department of Pharmacognosy, Sri Seshachala College of Pharmacy, Puttur Tirupati, Andhra Pradesh India.
3Vice Chancellor, Krishna University, Machillipatnam. Andhra Pradesh., India.
*Corresponding Author
Published In:
Volume - 14,
Issue - 5,
Year - 2021
ABSTRACT:
Aim and objective: The aim of present research work is to develop validated RP-HPLC stability indicating method for the quantification of Diroximel Fumarate in bulk and its pharmaceutical dosage forms. Materials and methods: Chromatographic method was carried on C18 column (Waters 250mm x 4.6mm, 5m). Mobile phase was prepared by mixing water: Acetonitrile: 85% OPA: in the ratio of 70:30. The flow rate was 0.1 mL/min and the injection volume was 20µL. The absorbance maxima of Diroximel Fumarate was measured at 215nm. The retention time was found to be 2.390 min. Result: The method was proved to be specific and linear in the range of 50-150µg/mL with correlation coefficient of 0.999. The % RSD for precision was found to be less than 2% and the mean percentage recovery was 100.15%. All the validation parameters were statistically validated according to ICH guidelines and were found to be within acceptance criteria. Conclusion: The developed method was simple, specific, precise, accurate and robust. The described HPLC method can be successfully employed for the analysis of Diroximel Fumarate.
Cite this article:
Rama chandrapuram Kiranjyothi, Mahalingam Balakrishnan, Kothapalli Bannoth Chandrasekhar. Stability Indicating RP-HPLC Method Development and Validation for Estimation of Diroximel Fumarate in bulk and its dosage forms. Research Journal of Pharmacy and Technology. 2021; 14(5):2603-7. doi: 10.52711/0974-360X.2021.00458
Cite(Electronic):
Rama chandrapuram Kiranjyothi, Mahalingam Balakrishnan, Kothapalli Bannoth Chandrasekhar. Stability Indicating RP-HPLC Method Development and Validation for Estimation of Diroximel Fumarate in bulk and its dosage forms. Research Journal of Pharmacy and Technology. 2021; 14(5):2603-7. doi: 10.52711/0974-360X.2021.00458 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-5-42
REFERENCES:
1. Fox, EJ, Vasquez, A, Grainger, W, et al. Gastrointestinal tolerability of delayed-release dimethyl fumarate in a multicenter, open-label study of patients with relapsing forms of multiple sclerosis. Int J MS Care 2016; 18(1): 9–18
2. K, Spinelli, KJ, Stuchiner, T, et al. Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center. Mult Scler 2018; 24(7): 942–950.
3. Gold, R, Kappos, L, Arnold, DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367: 1098–1107.
4. Gold, R, Arnold, DL, Bar-Or, A, et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. Mult Scler 2017; 23(2): 253–265.
5. Polman, CH, Reingold, SC, Banwell, B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69(2): 292–302.
6. Giles, K, Hanna, J, Wu, F, et al. Efficacy of delayed-release dimethyl fumarate in newly diagnosed and other early MS patients, and patients switching from interferon or glatiramer acetate, in routine medical practice: Interim results from Esteem. Mult Scler J 2017; 23(Suppl 3): 612.
7. Mehta, D, Miller, C, Arnold, DL, et al. Effects of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice. Neurology 2019; 92(15): e1724–e1738.
8. Giles, K, Hanna, J, Wu, F, et al. Efficacy of delayed-release dimethyl fumarate in newly diagnosed and other early MS patients, and patients switching from interferon or glatiramer acetate, in routine medical practice: Interim results from Esteem. Mult Scler J 2017; 23(Suppl 3): 612.
9. Mehta, D, Miller, C, Arnold, DL, et al. Effects of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice. Neurology 2019; 92(15): e1724–e1738.
10. Mirabella, M, Prosperini, L, Lucchini, M, et al. Safety and efficacy of dimethyl fumarate in multiple sclerosis: An Italian, multicenter, real-world study. CNS Drugs 2018; 32(10): 963–970.
11. International Conference on Harmonization of Technical Requirement for Registration of Pharmaceuticals for Human use. ICH harmonized tripartite guideline. Validation of analytical procedures text and methodology Q2 (R1).
12. ICH Harmonized Tripartite Guidelines Validation Of Analytical Procedures : Methodology, (1996), pages1-8